Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CureDuchenne and the Foundation to Eradicate Duchenne (FED), each has awarded grants of $250,000 to AVI BioPharma to support continued research and development of its exon skipping drug candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
Subscribe to our email newsletter
Leslie Hudson, president and CEO of AVI BioPharma, said: “AVI shares a commitment with the Foundation to Eradicate Duchenne and CureDuchenne to advance the research and development of disease-modifying drugs, treat DMD, and significantly help patients. We are grateful for the generous financial support of both organisations. This funding will help us continue to advance our drug candidates, including our lead drug candidate, AVI-4658, and move them closer to becoming new treatment options for patients.”
Debra Miller, president and founder of CureDuchenne, said: “Exon skipping holds promise as a treatment for Duchenne muscular dystrophy. CureDuchenne is very happy to support AVI BioPharma as it advances these treatments to boys with DMD as soon as possible. As the parent of a 13-year-old boy afflicted with DMD, I shall be very pleased to see AVI’s programs progress as quickly as possible.”
Joel Wood, president and founder of Foundation to Eradicate Duchenne, said: “The exon-skipping strategies being developed by AVI offer the greatest prospect for meaningful clinical therapies for the majority of boys and young men afflicted with this cruel disorder. We are gratified by the partnership with CureDuchenne, Children’s National Medical Center and AVI.”
CureDuchenne is a nonprofit organisation that raises awareness and funds research specifically aimed at taking on DMD.
Alexandria-based FED is a 501c3 charitable organisation established in 2001 to pursue therapeutics for DMD.
AVI BioPharma is focused on the discovery and development of RNA-based medicines utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to diseases and genetic disorders through several distinct mechanisms of action.